Your browser doesn't support javascript.
loading
The efficacy and safety of vonoprazan-amoxicillin dual therapy in eradicating Helicobacter pylori: a systematic review and meta-analysis.
Feng, Jia-Hui; Cheng, Jie; Lao, Yao-Jia; Huang, Kai; Mou, Juan-Li; Hu, Fan; Lin, Meng-Lu; Lin, Jun.
Afiliación
  • Feng JH; Department of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Cheng J; The Hubei Clinical Center & Key Laboratory of Intestinal & Colorectal Diseases, Wuhan, China.
  • Lao YJ; Department of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Huang K; The Hubei Clinical Center & Key Laboratory of Intestinal & Colorectal Diseases, Wuhan, China.
  • Mou JL; Department of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Hu F; The Hubei Clinical Center & Key Laboratory of Intestinal & Colorectal Diseases, Wuhan, China.
  • Lin ML; Department of Gastroenterology/Hepatology, Zhongnan Hospital of Wuhan University, Wuhan, China.
  • Lin J; The Hubei Clinical Center & Key Laboratory of Intestinal & Colorectal Diseases, Wuhan, China.
Eur J Med Res ; 28(1): 272, 2023 Aug 07.
Article en En | MEDLINE | ID: mdl-37550781
AIM: To evaluate the efficacy and safety of vonoprazan-amoxicillin (VA) dual therapy for radically eradicating Helicobacter pylori (H. pylori). METHODS: The PubMed, Cochrane Library, Embase, China National Knowledge  Infrastructure (CNKI) and Wanfang databases were searched up to July 7, 2022, to identify clinical trials comparing the efficacy of VA dual therapy and triple therapy for H. pylori eradication. After evaluating the quality of the included studies, random effects models were conducted, and risk ratios (RRs) with 95% confidence intervals (CIs) were calculated to estimate the efficacy and safety of each approach. RESULTS: Six publications (including four randomized controlled trials) involving 2019 patients were included in this meta-analysis. Overall, the eradication rate for VA dual therapy was 89.9%, while it was 85.2% for triple therapy based on other acid inhibitors. The eradication rate of H. pylori in the VA dual regimen group was higher than that in the PPI-based (omeprazole or lansoprazole) triple therapy group (RR = 1.15, 95% CI 1.07-1.23, p < 0.0001). However, the efficacy of VA dual therapy was comparable with VA-Clarithromycin (VAC) triple therapy (RR = 0.97, 95% CI 0.93-1.02). Besides, the incidence of adverse reactions in VA dual therapy was also lower than that in triple therapy (RR = 0.80, 95% CI 0.70-0.91, p = 0.0009). CONCLUSION: Compared with PPI-based triple therapy, VA dual therapy showed a better therapeutic effect, safety and patient compliance rate for eradicating H. pylori, which should be used as a novel curative strategy in the future.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Helicobacter pylori / Infecciones por Helicobacter Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Eur J Med Res Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Helicobacter pylori / Infecciones por Helicobacter Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Eur J Med Res Asunto de la revista: MEDICINA Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Reino Unido